

Sherman Oaks Family Medicine, Inc.
Donna Cashdan, D.O., F.A.A.F.P.
4835 Van Nuys Blvd. Suite #208
Sherman Oaks, CA 91403
T: 818-981-9880 F: 818-650-2894

SCANNED**Fax Cover Sheet**

To: Dr. Jaime S. Schwartz Date: 02/14/2023

Fax Number: (310) 747-5908 Phone: (310) 882-5454

Pages: 13

From: Kimberly MA@Dr. Cashdan's Office

RE: Faber, Taya DOB: 01/19/1979


Sx Date: 02/22/2023

* Please send operative ~~clearance~~, thank you!
Report

Confidential Health Information Enclosed. Health care information is personal and sensitive. It is being faxed to you after appropriate authorization from the Individual or under circumstances that do not require Individual authorization. You, the recipient, are obligated to maintain this information in a safe, secure and confidential manner. Re-disclosure without additional consent or authorization of the Individual or as permitted by law is prohibited. Unauthorized re-disclosure or failure to maintain the confidentiality of this information could subject you to penalties under Federal and/or State law.

The information contained in this facsimile transmission is privileged and confidential and is intended only for the use of the recipient listed above. If you are neither the intended recipient or the employee or agent of the intended recipient responsible for the delivery of this information, you are hereby notified that the disclosure, copying, use or distribution of this information is strictly prohibited. If you have received this transmission in error, please notify us immediately by telephone at 818-981-9880 to arrange for the return of the transmitted documents to us or to verify their destruction. Please contact us to verify receipt of this fax or to report problems with the transmission.

IMPORTANT: This facsimile transmission contains confidential information, some or all of which may be protected health information as defined by the Federal Health Insurance Portability & Accountability ACT (HIPAA) Privacy Rule. This transmission is intended for the exclusive use of the individual or entity to whom it is addressed and may contain information that is proprietary, privileged, confidential and/or exempt from disclosure under applicable law. If you are not the intended recipient (or an employee or agent responsible for delivering this facsimile transmission to the intended recipient), you are hereby notified that any disclosure, dissemination, distribution or copying of this information is strictly prohibited and may be subject to legal restriction or sanction. Please notify the sender by telephone (number listed above) to arrange the return or destruction of the information and all copies.

OK 

Surgery 2/22/23

Dr. Jaime S. Schwartz, M.D., F.A.C.S
Board Certified Plastic & Reconstructive Surgeon

SURGEON: Dr. Jaime S. Schwartz, MD FACS

PATIENT NAME: Taya Faber

DOB: 01/19/1979

SURGERY: - Breast Reduction & Lift (Bilateral Breast Reduction & Lift)

DATE OF SURGERY: \${SurgeryDateTime}

Anesthesia: **General** **Local**

REQUEST FOR PRE-OPERATIVE TESTS

I request the following clearance, bloodwork, and any applicable tests to be completed no later than 21 days prior to the surgery date. If not completed and received within 21 days of surgery, surgery may be postponed at additional cost.

Please fax the patients completed medical clearance with all lab results to (310) 747-5908.

Any questions please call (310) 882-5454.

- Medical Clearance
- DVT Prophylaxis Recommendation (see page 2)
- CBC
- COAGS (PT/ PTT/ INR)
- CMP
- LFT
- Prealbumin
- HbA1c
- B HCG (FEMALES)
- Urinalysis w/ C & S
- EKG
- Mammogram (All women ages 40+)
- Abdominal Ultrasound (rule out ventral, umbilical or previous surgical site hernia)
- Chest Xray
- Covid Test (Must be done 48 hours prior to surgery)
- Any other relevant tests based on patient's medical history

ADDITIONAL TESTING:

- Cardiac Clearance
- Pulmonary Clearance

Dr. Jaime S. Schwartz, M.D., F.A.C.S
Board Certified Plastic & Reconstructive Surgeon

Physical Examination

AGE: 44 SEX: F HEIGHT: 166 WEIGHT: 128
BP: 124/79 PULSE: 74 RESP: 12 TEMP: 97.2

GENERAL APPEARANCE AND SKIN:

HEAD AND NECK: WNL

LABS:

ENT:

EKG: Sinus Rhythm

THORAX & BREAST:

CXR: Pending

LUNGS:

MSK: WNL

CV:

NEURO: WNL

ABDOMEN:

GENITALIA: Deferred

IMPRESSION: Pre-op.

RECOMMENDATIONS:

*Our standard DVT prophylaxis includes the following:

1. Thigh-high TED hose placed in pre-op holding and worn for 1 week post-op
2. Knee-high SCDs placed pre-op and worn through discharge from PACU (if outpatient) or continuously at rest (if inpatient) until hospital discharge
3. Early ambulation post-op

*DVT PROPHYLAXIS USED:

Standard: _____

Other Chemical e.g. Lovenox, Xarelto: _____ Days: _____

(IF "LOVENOX" IS PREFERRED, PLEASE SPECIFY YOUR RECOMMENDATIONS FOR DURATION OF TIME.)

*PATIENT CLEARED FOR SURGERY:

YES

NO

MD SIGNATURE: _____ DATE: _____

MD NAME (printed): _____

Dr. Jaime S. Schwartz, M.D., F.A.C.S
Board Certified Plastic & Reconstructive Surgeon

Medical Clearance for Surgery

Please complete the following medical history and physical. Fill in the form legibly or please type. Unless otherwise noted, this must be received by our office a minimum of 21 days before surgery.

CHIEF COMPLAINT: Pre-op

ALLERGIES, DRUG SENSITIVITIES: Sulfa

REVIEW OF SYSTEMS:

PULM: 0

GU: 0

CV: 0

GYN: 0

GI: 0

NEURO: 0

PAST MEDICAL/SURGICAL HISTORY: (SURGERIES, ILLNESSES, ETC.)

- TOBACCO USE: 0
- ALCOHOL USE: 0
- BLEEDING TENDENCIES: 0
- TRANSFUSIONS: 0
- CURRENT MEDICATIONS: Prozac 60mg, Trazodone 25mg PRN
(please include medications that are recommended to be stopped prior to surgery and if so when)

Sherman Oaks Family Medicine, Inc.
4835 Van Nuys Blvd, Ste 208 Ste 208, Sherman Oaks, CA 91403
Office: 818-981-9880; Fax: 818-650-2894

Office Visit Note

*ElationHealth

Patient Name: Taya Faber

D.O.B.: 01/19/1979; 44 yrs, 0 mo at the time of visit

Seen by Mary Harton, D.O.

Date of Encounter: 02/02/2023

Exam Reason (CC): Pre Op

Subjective

1. 44 y/o female present for pre operative clearance. K.C
SX- Bilateral Breast Reduction and lift
SX Date- 2/22/23
2. Labs done already, Dr. Schwartz office ordered them. Got done yesterday. Waiting for labs on quest.
3. CXR ordered and sent to Radnet- Order given to patient.
4. Mammogram order needed.
5. EKG needed. Done today.
6. Went over medication list with the patient.

Allergy: Sulfa Antibiotics

- Meds:
- FLUoxetine 60 mg Cap sig: take 1 capsule by mouth once daily
 - traZODone 50 mg Tab sig: take 1 tablet by mouth at bedtime

ROS: GENERAL: Denies fever, chills weight loss or sleep abnormalities

EYES: Denies visual abnormalities

HENT: Denies nasal discharge, sore throat, ear pain or headache

RESP: No shortness of breath or wheezing

CVS: Denies chest pain, palpitations, irregular heart beat or leg edema

BREAST: Denies lump, skin changes

GI: Denies nausea, vomiting, diarrhea, abdominal pain or blood in stool

GU: Denies dysuria, hesitancy or hematuria

MSS: Denies joint pain or swelling

NS: Denies weakness, nerve pain or numbness

SKIN: No rashes

ENDOC: Denies polyuria, polydipsia, heat or cold intolerance

Objective

Vitals:

BP: 124/79 (Left

LMP- 01/19/2023) HR: 74 Temp: 97.2 °F Ht: 66 in. Wt: 128 lbs. [+0 from 128 lbs on 06/02/2022]

BMI: 20.66 [+0 from 20.66 on 06/02/2022] O₂: 98

PE: GENERAL: NAD, well nourished

EYES: PERRLE, EOMI

HENT: TM intact, throat clear

NECK: supple, no LAD

RESP: lungs BCTA

CVS: RRR without murmur

BREAST: deferred

ABDOM: no HSM, non distended, non tender, no mass or lesion

GU: deferred

MSS: muscles strength 5/5 bilat

NS: non focal

SKIN: no rash

PSYCH: affect appropriate

Assessment/Plan

1. Pre-op exam Z01.818

2. Screening for cardiovascular condition Z13.6

- EKG: sinus rhythm, 65 bpm, no acute ST changes.

3. Encounter for cosmetic procedure Z41.1

Proc: • Established Office Visit Comp focus hx/px/med dec

- Office Testing EKG w/ Interpretation

Care:

1. pt is undergoing low risk procedure. Functional Mets >4. CXR is pending. Labs have been in normal range.

Mammogram pending. If CXR and mammogram normal, pt may proceed with procedure with no further evaluation at this time.

Orders: Order CXR PA and Lat

Signed electronically by Mary Harton, D.O. on 02/02/2023 9:38 am in ⁺ElationHealth



Donna Cashdan, D.O.
Phone (818) 981-9880

**FABER, TAYA ▲**DOB: 01/19/1979
Sex: F
Phone: (206) 422-5594
Patient ID: 13420244Age: 44
Fasting: YSpecimen: ZU501341N
Requisition: 0000261
Report Status: PARTIAL / SEE REPORTCollected: 02/01/2023 07:25
Received: 02/01/2023 07:27
Reported: 02/02/2023 05:41Client #: 90211414
SCHWARTZ, JAIME S
JAIME SCHWARTZ, MD
240A S LA CIENEGA BLVD # 200
BEVERLY HILLS, CA 90211-3302
Phone: (310) 882-5454
Fax: (310) 882-5454

FASTING: YES

▲ URINALYSIS, COMPLETE W/REFLEX TO CULTURE

FINAL

Lab: EN

Analyte	Value		
COLOR (5778-6)	YELLOW	Reference Range: YELLOW	FINAL
APPEARANCE (5767-9)	CLEAR	Reference Range: CLEAR	FINAL
SPECIFIC GRAVITY (5811-5)	1.014	Reference Range: 1.001-1.035	FINAL
PH (5803-2)	6.5	Reference Range: 5.0-8.0	FINAL
GLUCOSE (25428-4)	NEGATIVE	Reference Range: NEGATIVE	FINAL
BILIRUBIN (5770-3)	NEGATIVE	Reference Range: NEGATIVE	FINAL
KETONES (2514-8)	NEGATIVE	Reference Range: NEGATIVE	FINAL
OCCULT BLOOD (5794-3)	NEGATIVE	Reference Range: NEGATIVE	FINAL
PROTEIN (20454-5)	NEGATIVE	Reference Range: NEGATIVE	FINAL
NITRITE (5802-4)	NEGATIVE	Reference Range: NEGATIVE	FINAL
LEUKOCYTE ESTERASE (5799-2)	NEGATIVE	Reference Range: NEGATIVE	FINAL
WBC (5821-4)	NONE SEEN	Reference Range: < OR = 5 /HPF	FINAL
RBC (13945-1)	0-2	Reference Range: < OR = 2 /HPF	FINAL
▲ SQUAMOUS EPITHELIAL CELLS (11277-1)	6-10	Reference Range: < OR = 5 /HPF	FINAL
▲ BACTERIA (5769-5)	FEW	Reference Range: NONE SEEN /HPF	FINAL
HYALINE CAST (5796-8)	NONE SEEN	Reference Range: NONE SEEN /LPF	FINAL
NOTE (8251-1)			FINAL

This urine was analyzed for the presence of WBC, RBC, bacteria, casts, and other formed elements. Only those elements seen were reported.

REFLEXIVE URINE CULTURE

FINAL

Lab: EN

Analyte	Value	
REFLEXIVE URINE CULTURE (630-4)		FINAL
NO CULTURE INDICATED		

COMPREHENSIVE METABOLIC PANEL

FINAL

Lab: EN

Analyte	Value	
GLUCOSE (2345-7)	80	Reference Range: 65-99 mg/dL
Fasting reference interval		FINAL
UREA NITROGEN (BUN) (3094-0)	14	Reference Range: 7-25 mg/dL

FINAL

FABER, TAYA (ZD501341N)

1 / 4

2/2/23

CREATININE (2160-0)	0.73	Reference Range: 0.50-0.99 mg/dL	FINAL
EGFR (98979-8)	104	Reference Range: > OR = 60 mL/min/1.73m2	FINAL
The eGFR is based on the CKD-EPI 2021 equation. To calculate the new eGFR from a previous Creatinine or Cystatin C result, go to https://www.kidney.org/professionals/kdoqi/gfr%5Fcalculator			
BUN/CREATININE RATIO (3097-3)	NOT APPLICABLE	Reference Range: 6-22 (calc)	FINAL
SODIUM (2951-2)	137	Reference Range: 135-146 mmol/L	FINAL
POTASSIUM (2823-3)	4.4	Reference Range: 3.5-5.3 mmol/L	FINAL
CHLORIDE (2075-0)	101	Reference Range: 98-110 mmol/L	FINAL
CARBON DIOXIDE (2028-9)	29	Reference Range: 20-32 mmol/L	FINAL
CALCIUM (17861-6)	9.6	Reference Range: 8.6-10.2 mg/dL	FINAL
PROTEIN, TOTAL (2885-2)	8.0	Reference Range: 6.1-8.1 g/dL	FINAL
ALBUMIN (1751-7)	4.7	Reference Range: 3.6-5.1 g/dL	FINAL
GLOBULIN (10834-0)	3.3	Reference Range: 1.9-3.7 g/dL (calc)	FINAL
ALBUMIN/GLOBULIN RATIO (1759-0)	1.4	Reference Range: 1.0-2.5 (calc)	FINAL
BILIRUBIN, TOTAL (1975-2)	0.3	Reference Range: 0.2-1.2 mg/dL	FINAL
ALKALINE PHOSPHATASE (6768-6)	72	Reference Range: 31-125 U/L	FINAL
AST (1920-8)	17	Reference Range: 10-30 U/L	FINAL
ALT (1742-6)	13	Reference Range: 6-29 U/L	FINAL

PREALBUMIN

PEND

Lab: EN

Analyte	Value
PREALBUMIN (14338-8)	PEND

HEPATIC FUNCTION PANEL

FINAL

Lab: EN

Analyte	Value
PROTEIN, TOTAL (2885-2)	8.0 Reference Range: 6.1-8.1 g/dL
ALBUMIN (1751-7)	4.7 Reference Range: 3.6-5.1 g/dL
GLOBULIN (10834-0)	3.3 Reference Range: 1.9-3.7 g/dL (calc)
ALBUMIN/GLOBULIN RATIO (1759-0)	1.4 Reference Range: 1.0-2.5 (calc)
BILIRUBIN, TOTAL (1975-2)	0.3 Reference Range: 0.2-1.2 mg/dL
BILIRUBIN, DIRECT (1968-7)	0.1 Reference Range: < OR = 0.2 mg/dL
BILIRUBIN, INDIRECT (1971-1)	0.2 Reference Range: 0.2-1.2 mg/dL (calc)
ALKALINE PHOSPHATASE (6768-6)	72 Reference Range: 31-125 U/L
AST (1920-8)	17 Reference Range: 10-30 U/L
ALT (1742-6)	13 Reference Range: 6-29 U/L

PARTIAL THROMBOPLASTIN TIME, ACTIVATED

FINAL

Lab: EN

Analyte	Value
---------	-------

HCG, TOTAL, QN

FINAL

Lab: EN

Analyte**Value****HCG, TOTAL, QN (21198-7)**

<3 mIU/mL

FINAL

Reference Range

Nonpregnant or premenopausal <5

Postmenopausal <10

Values from different assay methods may vary.
The use of this assay to monitor or to diagnose patients with cancer or any condition unrelated to pregnancy has not been cleared or approved by the FDA or the manufacturer of the assay.

HEMOGLOBIN A1c

FINAL

Lab: EN

Analyte**Value****HEMOGLOBIN A1c (4548-4)**

5.1 Reference Range: <5.7 % of total Hgb

FINAL

For the purpose of screening for the presence of diabetes:

<5.7% Consistent with the absence of diabetes
5.7-6.4% Consistent with increased risk for diabetes (prediabetes)
> or =6.5% Consistent with diabetes

This assay result is consistent with a decreased risk of diabetes.

Currently, no consensus exists regarding use of hemoglobin A1c for diagnosis of diabetes in children.

According to American Diabetes Association (ADA) guidelines, hemoglobin A1c <7.0% represents optimal control in non-pregnant diabetic patients. Different metrics may apply to specific patient populations. Standards of Medical Care in Diabetes(ADA).

Performing Sites

EN Quest Diagnostics-West Hills, 8401 Fallbrook Ave, West Hills, CA 91304-3226 Laboratory Director: Tab Tooichinda MD

Key

🚨 Priority Out of Range ▲ Out of Range (PEND) Pending Result (PRE) Preliminary Result (FINAL) Final Result (RE) Reissued Result

Quest, Quest Diagnostics, the associated logo, Nichols Institute, Interactive Insights and all associated Quest Diagnostics marks are the registered trademarks of Quest Diagnostics. All third party marks - ® and ™ - are the property of their respective owners. Privacy policy can be found at: <http://questdiagnostics.com/home/privacy-policy/online-privacy.html>. © 2022 Quest Diagnostics Incorporated. All rights reserved.

PARTIAL THROMBOPLASTIN TIME, ACTIVATED

(14979-9)

27 Reference Range: 23-32 sec

FINAL

This test has not been validated for monitoring unfractionated heparin therapy. For testing that is validated for this type of therapy, please refer to the Heparin Anti-Xa assay (test code 30292).

For additional information, please refer to <http://education.QuestDiagnostics.com/faq/FAQ159> (This link is being provided for informational/educational purposes only.)

CBC (INCLUDES DIFF/PLT)

FINAL

Lab: EN

Analyte	Value	
WHITE BLOOD CELL COUNT (6690-2)	5.3	Reference Range: 3.8-10.8 Thousand/uL
RED BLOOD CELL COUNT (789-8)	4.14	Reference Range: 3.80-5.10 Million/uL
HEMOGLOBIN (718-7)	13.3	Reference Range: 11.7-15.5 g/dL
HEMATOCRIT (4544-3)	39.6	Reference Range: 35.0-45.0 %
MCV (787-2)	95.7	Reference Range: 80.0-100.0 fL
MCH (785-6)	32.1	Reference Range: 27.0-33.0 pg
MCHC (786-4)	33.6	Reference Range: 32.0-36.0 g/dL
RDW (788-0)	12.1	Reference Range: 11.0-15.0 %
PLATELET COUNT (777-3)	263	Reference Range: 140-400 Thousand/uL
MPV (776-5)	9.9	Reference Range: 7.5-12.5 fL
ABSOLUTE NEUTROPHILS (751-8)	3191	Reference Range: 1500-7800 cells/uL
ABSOLUTE LYMPHOCYTES (731-0)	1484	Reference Range: 850-3900 cells/uL
ABSOLUTE MONOCYTES (742-7)	413	Reference Range: 200-950 cells/uL
ABSOLUTE EOSINOPHILS (711-2)	170	Reference Range: 15-500 cells/uL
ABSOLUTE BASOPHILS (704-7)	42	Reference Range: 0-200 cells/uL
NEUTROPHILS (770-8)	60.2	%
LYMPHOCYTES (736-9)	28.0	%
MONOCYTES (5905-5)	7.8	%
EOSINOPHILS (713-8)	3.2	%
BASOPHILS (706-2)	0.8	%

PROTHROMBIN TIME-INR

FINAL

Lab: EN

Analyte	Value	
INR (6301-6)	1.0	
Reference Range	0.9-1.1	
Moderate-intensity Warfarin Therapy	2.0-3.0	
Higher-intensity Warfarin Therapy	3.0-4.0	
PT (5902-2)	10.4	Reference Range: 9.0-11.5 sec

For additional information, please refer to <http://education.questdiagnostics.com/faq/FAQ104> (This link is being provided for informational/educational purposes only.)

MINK RADIOLOGIC IMAGING

JAIME SCHWARTZ
240 S LA CIENEGA BLVD, STE 200
BEVERLY HILLS CA 90211

BEVERLY HILLS LOCATION
8670 Wilshire Blvd. Suite 101 • Beverly Hills, CA 90211
PHONE: (310) 358-2100 • FAX: (310) 358-2131

Patient Name:	FABER, TAYA	Patient #:	9565450	
Date of Birth:	01/19/1979	Age:	44	Gender: Female
Procedure Date:	02/09/2023			
Accession #:	114679530			
Procedure(s):	XR CHEST PA LAT 2 VIEWS			

IMPRESSION:

1. No abnormalities are noted.

CLINICAL INFORMATION: History of "pulmonary infiltrate."

TECHNIQUE: PA and lateral views were obtained.

COMPARISON: None

FINDINGS:

The heart is normal size. There are no abnormalities of the mediastinum or hila. No parenchymal or pleural abnormalities are noted. The pulmonary vascularity is normal. There are no bony abnormalities.

RPTAT:MINKBH

MARSHALL BEIN, MD
CC:

Electronically Signed by: MARSHALL BEIN, MD on 02-09-2023 03:24 PM

This fax was sent with GFI FaxMaker fax server. For more information, visit: <http://www.gfi.com>

Signed electronically by Greer Loveman-Krelle, NP on 02/14/2023 9:24 am in *Elation-Health

02-13-2023 3:20 PM

Fax Services

→ MANUAL 10353336 Dr

pg 1 of 1



SCHWARTZ, JAIME, MD
240 S LA CIENEGA SUITE 200
BEVERLY HILLS, CA 90211

Patient: FABER, TAYA
MRN: 878704, Accession: 10353336
Date of Birth: 01/19/1979

Copies To:

Date of Service: 02/10/2023

EXAM DESCRIPTION:
DIGITAL DIAGNOSTIC BILATERAL MAMMOGRAM

CLINICAL HISTORY:
Patient presents for annual bilateral mammography. She has no current breast related complaints.

COMPARISON:
September 14, 2021

FINDINGS:
The breasts are heterogeneously dense, which may obscure small masses. There are no suspicious masses, clusters of microcalcifications or areas of architectural distortion to suggest malignancy. There are no abnormal appearing lymph nodes within either axilla. There is no significant change when compared to prior studies.

This study has been analyzed by the radiologist, as well as reviewed by an automated computer-aided detection system.

IMPRESSION:
There is no mammographic evidence of malignancy within either breast. There is no significant interval change when compared to prior studies.

BI-RADS 2 BENIGN

RECOMMENDATION:
Routine clinical surveillance is advised. Annual bilateral screening mammography is recommended, due in February 2024 in accordance with the American College of Radiology recommendations.
Unit Location: CM-D2WY0R3

Electronically signed by:

Lakshmi Tegulapalle, D.O.
www.hillmedical.com

Dictated: 02/10/2023 17:09

Transcribed :

Dictated by: Lakshmi C. Tegulapalle D.O on 02/10/2023 17:09



Christylin G. Smith, M.D.	Jonathan T. Pomeroy, M.D.	Lakshmi C. Tegulapalle, D.O.	Shashank K. Lohar, M.D.	Demetrius S. St. John, M.D.
David A. Tuma, M.D.	Thomas P. Lutz, M.D.	David M. Kuznetsov, M.D.	Harishankar K. Kulkarni, M.D.	David B. Brown, M.D.
Andrew T. Shih, M.D.	Robert J. Goss, M.D.	James B. Cunningham, M.D.	Eric J. A. Mancini, M.D.	
Sahar A. Toghiani, M.D.	Paul M. Poma, M.D.	Gregory J. Lurie, M.D.	David B. Glickman, M.D.	

625 S. Fair Oaks Ave. Suite 140 | Pasadena, CA 91105 | (626)793-6141 | (626)796-0172

Signed electronically by Greer Loveman-Krelle, NP on 02/14/2023 9:25 am in Elation Health

SINUS RHYTHM
INCOMPLETE RIGHT BUNDLE BRANCH BLOCK
OTHERWISE NORMAL ECG

HR: 65 BPM

Axis:
P 52 °
QRS 54 °
T 3 °

Intervals:
RR 928 ms
P 110 ms
PR 170 ms
QRS 90 ms
QT 398 ms
QTc 415 ms

5.79

P (II) 0.16 mV
S (V1) -0.98 mV
R (V5) 1.89 mV
Sokol. 3.27 mV

UNCONFIRMED REPORT



SCANNED

